Macquarie Group LTD Xenon Pharmaceuticals Inc. Transaction History

Macquarie Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$30.79 - $39.82 $16,595 - $21,462	-539 Reduced 80.33%	132 $24,000
Q1 2022 May 16, 2022	SELL	$25.09 - $33.13 $71,330 - $94,188	-2,843 Reduced 80.9%	671 $21,000
Q3 2021 Nov 12, 2021	BUY	$14.86 - $19.45 $44,208 - $57,863	2,975 Added 551.95%	3,514 $54,000
Q1 2021 May 14, 2021	SELL	$13.65 - $21.31 $3,494 - $5,455	-256 Reduced 32.2%	539 $10,000
Q2 2020 Aug 11, 2020	BUY	$10.21 - $14.9 $8,116 - $11,845	795 New	795 $10,000
Q1 2018 May 11, 2018	SELL	$2.7 - $4.9 $8,910 - $16,170	-3,300 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$2.2 - $3.25 $7,260 - $10,725	3,300	3,300 $9,000

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.